Enimmune corporation
Enimmune Corporation engages in the research, development, and sale of drugs in Taiwan. The company offers EnVAX-A71, AimFlu-S(QIS), tetanus vaccine adsorbed suspension for injection, COVID-19 Ag rapid test, vaccines, test reagents, and related western medicines, as well as biotechnology services. It is also involved in the development of vaccines for the prevention of infectious diseases, includ… Read more
Enimmune corporation (6564) - Total Assets
Latest total assets as of June 2025: NT$521.26 Million TWD
Based on the latest financial reports, Enimmune corporation (6564) holds total assets worth NT$521.26 Million TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Enimmune corporation - Total Assets Trend (2019–2024)
This chart illustrates how Enimmune corporation’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Enimmune corporation - Asset Composition Analysis
Current Asset Composition (December 2024)
Enimmune corporation's total assets of NT$521.26 Million consist of 81.3% current assets and 18.7% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 67.0% |
| Accounts Receivable | NT$12.84 Million | 1.8% |
| Inventory | NT$22.34 Million | 3.1% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$104.17 Million | 14.4% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Enimmune corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Enimmune corporation's current assets represent 81.3% of total assets in 2024, an increase from 60.8% in 2019.
- Cash Position: Cash and equivalents constituted 67.0% of total assets in 2024, up from 37.2% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, a decrease from 39.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 14.4% of total assets.
Enimmune corporation Competitors by Total Assets
Key competitors of Enimmune corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Enimmune corporation - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Enimmune corporation generates 0.06x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Enimmune corporation is currently not profitable relative to its asset base.
Enimmune corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.41 | 2.70 | 19.06 |
| Quick Ratio | 1.26 | 2.66 | 17.94 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$109.37 Million | NT$ 410.80 Million | NT$ 342.97 Million |
Enimmune corporation - Advanced Valuation Insights
This section examines the relationship between Enimmune corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.56 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 19.7% |
| Total Assets | NT$723.70 Million |
| Market Capitalization | $15.66 Million USD |
Valuation Analysis
Below Book Valuation: The market values Enimmune corporation's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Enimmune corporation's assets grew by 19.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Enimmune corporation (2019–2024)
The table below shows the annual total assets of Enimmune corporation from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$723.70 Million | +19.65% |
| 2023-12-31 | NT$604.83 Million | -21.97% |
| 2022-12-31 | NT$775.09 Million | +27.05% |
| 2021-12-31 | NT$610.07 Million | -7.23% |
| 2020-12-31 | NT$657.62 Million | +99.66% |
| 2019-12-31 | NT$329.38 Million | -- |